Imexpharm Corporation reported VND2,205 billion (US$87.3 million) in net revenue for 2024, marking a 10.6% year-on-year increase.

HYTN will endeavour to amend its licenses and/or certificates, establish a stability program, and implement GMP-compliant processes tailored for vape cartridge production.

Sanofi (NASDAQ:SNY) has received EU regulatory approval for its drug Sarclisa for the treatment of newly diagnosed multiple myeloma patients. The drug was approved for use in combination with a ...

Imexpharm Corporation has announced its 2024 financial results with net revenue reaching VND2,205 billion, up 10.6 percent year on year, driven by robust growth in ETC channel and high-quality ...

Venus Remedies secures EU GMP renewal from Infarmed, strengthens European market presence: Our Bureau, Bengaluru Wednesday, January 22, 2025, 15:30 Hrs [IST] Venus Remedies has an ...